Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Bowel Disease (IBD) and Gastrointestinal Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCR9 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Full-Length Expression (GPCR) | CCR9 Lentivirus Premade Particles. HEK293-expressed, full-length ORF for stable cell lines. Preserves native multipass GPCR conformation and glycosylation. Endotoxin <1 EU/µg. | View CCR9 Products |
| Ligand (CCL25) | CCL25 (TECK) Recombinant Protein. High purity (>95%), sequence verified, endotoxin controlled. For competitive binding, calcium flux, and chemotaxis assays. | View CCL25 Products |
| ECD Antigen | CCR9 ECD-Fc Fusion Protein. HEK293-expressed, for SPR/ELISA screening. | View CCR9 Products |
| Benchmark Antibody | Anti-CCR9 Reference Antibody. Recombinant positive control for Flow Cytometry. | View CCR9 Products |
| Gene Silencing | CCR9 siRNA Set. Three pre-designed siRNAs for knockdown validation and specificity controls. | View CCR9 Products |
| Related Target: ITGA4 | Integrin alpha-4. Functional partner in α4β7-mediated gut homing; combination therapy target in IBD. | View ITGA4 Products |
| Related Target: CCR7 | Chemokine receptor 7. Synergistic lymphocyte trafficking pathway; egress vs. gut homing studies. | View CCR7 Products |
| Related Target: CCR10 | Chemokine receptor 10. Skin-homing receptor; comparative tissue specificity profiling. | View CCR10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity (7-TM domain preservation) | Lentivirus-mediated stable cell lines ensure native membrane topology and correct ligand-binding pocket. |
| Functional Ligand Screening & Displacement | High-purity CCL25 (>95%) for reliable receptor internalization and calcium flux assays; endotoxin controlled. |
| Lack of Controls & Specificity | Clinical benchmark antibodies and validated siRNA included. Chemokine receptor subfamily panel (CCR3, CCR7, CCR10) available for cross-reactivity screening. |
| Species Cross-Reactivity (Preclinical Safety) | Human/Cyno/Mouse CCR9 ortholog proteins available (>95% purity, Mass Spec verified). |
| False Positives | Sequence-verified siRNA and multi-panel counter-screening to eliminate off-target signals. |
Live CCR9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CCR9 therapeutic landscape is evolving rapidly. Following the strategic repositioning of first-generation small-molecule antagonists (e.g., vercirnon/CCX282 by ChemoCentryx/Amgen in Crohn's disease), current R&D emphasizes CCR9's role in gastrointestinal malignancy metastasis and tissue-specific immune modulation. Major players focus on inflammatory bowel disease (Crohn's disease, ulcerative colitis) and select oncological indications like T-cell acute lymphoblastic leukemia (T-ALL) and colorectal cancer. The next wave of discovery targets the CCR9-CCL25 axis through highly specific monoclonal antibodies, allosteric modulators, antibody-drug conjugates (ADCs), and engineered cell trafficking (e.g., CAR-T gut-homing). Combination therapies with integrin inhibitors (e.g., α4β7) are also a key trend to achieve deeper remission without systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | ChemoCentryx (Amgen), Boehringer Ingelheim | Crohn's Disease, Celiac Disease (repositioning) | Whole-cell binding assays using Lentivirus-stable lines to preserve 7-TM conformation. |
| Monoclonal Antibody | Various Biotechs | IBD, Gastrointestinal Cancers (metastasis inhibition) | Cross-species binding validation (Human/Cyno/Mouse CCR9 ECD-Fc proteins). Flow cytometry on native GPCR cells. |
| Antibody-Drug Conjugate (ADC) | Emerging Programs | CCR9+ Solid Tumors (Colorectal) | Internalization assays on Lentivirus-transduced cell lines; endotoxin-controlled reagents. |
| Combination Therapies | Academic & Pharma | Refractory IBD | Selectivity assays needing CCL25 and synergistic target panels (ITGA4, CCR7). |
| Cell Therapy Engineering | CAR-T Developers | Tissue-specific homing optimization | Functional CCR9 expression validation via flow cytometry using Lentivirus particles. |
Note: Approximately 60% of current projects focus on small molecule repositioning (anti-inflammatory), while 40% target biologics (oncology); biologics share is expected to surpass within 5 years.